MedCloud Minute
The MedCloud Minute blog is researched, fact-checked, edited and updated by the editors of MedCloudInsider.com, with writing assistance from AI. To submit your company's press release for consideration, contact [email protected].
Mira Precision Health, specialists in precision medicine diagnostics, has announced the U.S. launch of ToxNav Advantage, an AI-based clinical decision support platform, at the 2026 ASCO Gastrointestinal Cancers Symposium. The software is designed to help oncologists assess and manage treatment-related toxicity risk by analyzing patient-specific data alongside therapy characteristics. Mira intends for ToxNav Advantage to support more informed treatment planning, particularly for gastrointestinal cancers where adverse effects can limit dose intensity or lead to early discontinuation.
More
Posted by MedCloudInsider Editors on 01/05/20260 comments
The Veterans Health Venture Studio (VHVS), an engine designed to develop the pipeline of innovation, expands its Make-a-thon program, an innovation initiative that pairs VA clinicians, engineers, designers and veterans to rapidly develop solutions to unmet needs in health care delivery and daily living. The Make-a-thon is supported by the VA's Office of Healthcare, The American Legion and Microsoft. At its core, the program is powered by Microsoft with expert innovative training, experts and mentorship. The program focuses on hands-on collaboration, enabling teams to prototype assistive devices, clinical tools, and workflow improvements in short, intensive sprints. VA officials want the approach to help translate frontline insights into practical solutions more quickly than traditional procurement or research pathways.
More
Posted by MedCloudInsider Editors on 01/05/20260 comments
Link Cell Therapies, a biotechnology oncology cell therapy company, has officially launched with the mission of accelerating the development of next-generation CAR-T therapies targeting both liquid and solid tumours. The company plans to apply innovations in cell engineering, tumor microenvironment modulation, and safety switches to overcome longstanding challenges that have limited CAR-T efficacy in solid malignancies. Link says its initial programs will advance through preclinical validation with IND-enabling goals, targeting tumor antigens with broad expression profiles and engineered features designed to improve persistence and reduce off-target toxicity.
More
Posted by MedCloudInsider Editors on 12/15/20250 comments
BioTec, a specialized bio company, has introduced two new sulfur-based products designed for industrial and agricultural markets, expanding its portfolio with materials intended to improve performance in applications such as advanced coatings and soil treatment. The company highlighted its new offerings at recent domestic and international exhibitions, emphasizing its formulation technology and its potential to meet evolving customer specifications. BioTec says the products leverage its sulfur-derivative expertise and production infrastructure to deliver consistent quality and scalable supply.
More
Posted by MedCloudInsider Editors on 12/15/20250 comments
Astrin Biosciences, a cancer intelligence company, has established a scientific advisory board to support the development of its AI-enabled proteomics platform for early cancer detection. The new board includes clinicians and researchers with backgrounds in oncology, biomarker discovery and machine learning, who will advise on study design, validation strategies and clinical translation. The development of the board comes post the launch of Astrin's Certitude Breast, a non-imaging screening test that can detect breast cancer in early stages. Astrin claims expert input is critical as it advances toward larger trials and potential regulatory pathways.
More
Posted by MedCloudInsider Editors on 12/08/20250 comments
Inductive Bio, an AI drug discovery partner, has received an award of up to $21 million to advance AI-driven toxicity models intended to improve drug safety assessment and reduce downstream development risk. The company will work with leading academic and biopharmaceutical partners to generate datasets, validate predictive models and evaluate how AI can better characterize off-target effects early in the R&D cycle. Inductive Bio aims to use the initiative to address persistent gaps in preclinical toxicity screening, where conventional models often fail to capture complex biological interactions that later lead to trial delays or program termination.
More
Posted by MedCloudInsider Editors on 12/08/20250 comments
ALR Technologies, a data management company, plans to relaunch its GluCurve Pet Continuous Glucose Monitor (CGM) in January 2026. The device is designed to help veterinarians and pet owners monitor glucose levels in diabetic cats and dogs through continuous, automated readings rather than periodic manual tests. Blood sugar readings are uploaded to the ALRT Veterinary Web Portal so that vets can easily monitor readings and adjust insulin levels accordingly for their patients.
More
Posted by MedCloudInsider Editors on 12/08/20250 comments
CaliberMRI, an automation software and imaging phantoms company, has introduced the qDisc, a new quantitative MRI phantom designed to augment the functionality of the Medium ACR Phantom commonly used in clinical quality-assurance workflows. The qDisc provides stable reference materials for diffusion, T1/T2 relaxation and temperature measurements, allowing imaging teams to perform more comprehensive scanner performance checks without adding complex new equipment. The company says the device provides a practical option to gather metrics during routine scans. The harmonization of MRI scanners and AI software for analysis can be done using the qDisc, which complements CaliberMRI's existing offerings.
More
Posted by MedCloudInsider Editors on 12/01/20250 comments
Hoppr and Ferrum Health, an AI-insights service provider, have announced a partnership to launch a full foundation-model development suite designed specifically for healthcare organizations. The platform will allow hospitals, research centers and developers to build or fine-tune large medical AI models using their own imaging and clinical datasets while keeping all data within a secure, compliance-focused environment. The integrated suite offers development tooling, data curation, model training, evaluation frameworks, interoperability and seamless deployment into Ferrum's governance layer.
More
Posted by MedCloudInsider Editors on 12/01/20250 comments
ScreenPoint Medical, an AI-powered technological company specializing in breast imaging to help detect breast cancer, showcased new advancements to its Transpara Breast AI Suite at RSNA 2025. The updated suite provides risk scoring, lesion detection and triage tools designed to help radiologists prioritize cases and identify cancers earlier, particularly in dense breast tissue. The company noted that Transpara is already in clinical use in more than 30 countries and is designed to integrate with existing PACS and reading workflows without major process changes.
More
Posted by MedCloudInsider Editors on 12/01/20250 comments
Hoth Therapeutics, a clinical-stage biopharmaceutical company, has been accepted into the NVIDIA Connect Program, providing the company with access to NVIDIA’s accelerated computing and AI development resources. Hoth plans to use these tools to speed computational modeling, data processing, and target evaluation across its early-stage pipeline, which includes programs in dermatology, inflammation, and oncology. The company said the program will support both internal research and collaborations by enabling larger-scale simulations and AI-driven analysis. The connection provides Hoth Therapeutics with GPU-accelerated developer tools, SDKs and APIs as well as co-marketing for increased visibility.
More
Posted by MedCloudInsider Editors on 11/24/20250 comments
Aperture Therapeutics, a preclinical biotechnology company, has announced a new development candidate targeting CD33, a receptor implicated in dysfunctional microglial activity in frontotemporal dementia (FTD) and amyotrophic lateral sclerosis (ALS). The therapy is designed to restore microglial homeostasis by modulating CD33 signaling, which research shows can reduce harmful inflammatory responses and improve debris clearance in the central nervous system. The company reports that preclinical work supports CD33 as a viable path toward slowing or modifying disease progression, and the candidate will advance into IND-enabling studies.
More
Posted by MedCloudInsider Editors on 11/24/20250 comments